MSFS
SONN

Main Street Financial Solutions’s Sonnet BioTherapeutics SONN Stock Holding History

Main Street Financial Solutions’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4
Closed -$3K – 470
2022
Q2 		$3K Hold
4
– – ﹤0.01% 451
2022
Q1 		$4K Hold
4
– – ﹤0.01% 442
2021
Q4 		$4K Hold
4
– – ﹤0.01% 467
2021
Q3 		$6K Hold
4
– – ﹤0.01% 444
2021
Q2 		$17K Hold
4
– – ﹤0.01% 435
2021
Q1 		$24K Hold
4
– – ﹤0.01% 415
2020
Q4 		$24K Buy
+4
New +$25.4K ﹤0.01% 375

Other funds holding SONN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Main Street Financial Solutions's SONN Position: Q3 2022 in Review

Main Street Financial Solutions sold out of Sonnet BioTherapeutics (SONN) in Q3 2022, closing a stake of 4 shares — an estimated $3K sold.

Main Street Financial Solutions first reported a position in SONN in Q4 2020 and held it in 7 quarters. The position peaked at $24K in Q1 2021. 10 funds tracked by Wall St. Rank hold SONN as of Q3 2022.

  • Main Street Financial Solutions reported no remaining Sonnet BioTherapeutics position as of Q3 2022 after selling out during the quarter.
  • Main Street Financial Solutions sold 4 Sonnet BioTherapeutics shares in Q3 2022, an estimated $3K.
  • Main Street Financial Solutions first reported a position in Sonnet BioTherapeutics in Q4 2020 and held it in 7 quarters.
  • Main Street Financial Solutions's Sonnet BioTherapeutics position peaked at $24K in Q1 2021.
  • 10 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2022.

Based on Main Street Financial Solutions's 13F filing for Q3 2022, filed 24 Oct 2022.